Search bioRxivSearch

Biology subjects

Zimmermann, M.

Publications and source records attributed to Zimmermann, M..

3 recordsLinked to original sources

Two parallel pathways implement robust propionate catabolism and detoxification in mycobacteria

Tuberculosis remains a major global health threat with over 1.5 million deaths each year. Mycobacterium tuberculosis success story is related to a flexible metabolism, allowing growth despite restrictive conditions within the human host.\n\nHost lipids stores are a major carbon source in vivo. Their catabolism yields propionyl-CoA, which is processed by two parallel pathways, the methylmalonyl CoA pathway and the methylcitrate pathway. Both pathways are considered potential drug targets. The methylcitrate pathway is upregulated in the pathological context. However, intermediates of this pathway can be cytotoxic and Mtbs preference for its usage remains unclear.\n\nWe combine thermodynamic kinetic modeling, quantitative proteomics and time-resolved metabolomics to characterize the interplay between the two pathways and to show their functionalities in an efficient and fast propionate catabolism.\n\nWe find that the methylcitrate pathway acts as a transcriptionally regulated, high capacity catabolic pathway due to its favorable thermodynamics and metabolic control distribution. In contrast, the methylmalonyl pathway is constitutively fulfilling biosynthetic tasks and can quickly detoxify propionate pulses, but is thermodynamically restricted to lower capacity.

systems biology

Identifying drug-gene interactions from CRISPR knockout screens with drugZ

Chemogenetic profiling enables the identification of gene mutations that enhance or suppress the activity of small molecules. This knowledge provides insights into drug mechanism-of-action, genetic vulnerabilities, and resistance mechanisms, all of which may help stratify patient populations. We present drugZ, an algorithm for identifying both synergistic and suppressor chemogenetic interactions from highly sensitive CRISPR screens, available at github.com/hart-lab/drugz. In screens for interactions with a poly(ADP-ribose) polymerase (PARP) inhibitor, DrugZ identifies a greater fraction of the homologous recombination repair pathway than contemporary methods, and confirms KEAP1 loss as a resistance factor for ERK inhibitors.

bioinformatics

Antibodies set boundaries limiting microbial metabolite penetration and the resultant mammalian host response

Although the mammalian microbiota is well-contained within the intestine and on other body surfaces, it profoundly shapes development and metabolism of almost every host organ, presumably through pervasive microbial metabolite penetration. The challenge is that most metabolites can be of both host and microbial origin. We developed a model to distinguish between microbial and host metabolites by stable isotope tracing using fully 13C-labelled live non-replicating Escherichia coli, differentiating 12C and 13C isotopes with high-resolution mass spectrometry. Hundreds of microbial compounds penetrated across 23 host tissues and fluids after intestinal exposure: subsequent 12C host metabolome signatures included lipidemia, reduced glycolysis and inflammation. Mucosal barrier maturation with transient microbial exposure increased early clearance of penetrant bacterial metabolites from the small intestine into the urine, independently of antibody induction. Induced antibodies curtailed microbial metabolite exposure at the intestinal surface, by accelerating intestinal bacterial transit into the colon where metabolite transport mechanisms are limiting.

immunology